ELV (Elevance Health) Research & Development : $0 Mil (TTM As of Sep. 2024)

View and export this data going back to 2001. Start your Free Trial

What is Elevance Health Research & Development?

Research & Development is the aggregate amount of research and development expenses during the year. Elevance Health's Research & Development for the three months ended in Sep. 2024 was $0 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Sep. 2024 was $0 Mil.

Elevance Health Research & Development Historical Data

The historical data trend for Elevance Health's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Elevance Health Research & Development Chart

Elevance Health Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Research & Development

Get a 7-Day Free Trial

Elevance Health Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
Research & Development	Get a 7-Day Free Trial															-	-	-	-	-

Elevance Health Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $0 Mil.

Elevance Health (NYSE:ELV) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

Elevance Health Research & Development Related Terms

Thank you for viewing the detailed overview of Elevance Health's Research & Development provided by GuruFocus.com. Please click on the following links to see related term pages.

Elevance Health Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Healthcare Plans » Elevance Health Inc (NYSE:ELV) » Definitions » Research & Development

Comparable Companies

Traded in Other Exchanges

ELV:Mexico 1ANTM:Italy 0HG8:UK A58:Germany A58:Germany E1LV34:Brazil ELV:Austria

Address

220 Virginia Avenue, Indianapolis, IN, USA, 46204

Website

https://www.elevancehealth.com

Elevance Health remains one of the leading health insurers in the U.S., providing medical benefits to 47 million medical members as of December 2023. The company offers employer, individual, and government-sponsored coverage plans. Elevance differs from its peers in its unique position as the largest single provider of Blue Cross Blue Shield branded coverage, operating as the licensee for the Blue Cross Blue Shield Association in 14 states. Through acquisitions, such as the Amerigroup deal in 2012 and MMM in 2021, Elevance's reach expands beyond those states through government-sponsored programs such as Medicaid and Medicare Advantage plans, too.

Executives

Kendrick Charles Morgan Jr	officer: EVP & President, Commercial	220 VIRGINIA AVE, INDIANAPOLIS IN 46204
Ramiro G Peru	director	WELLPOINT, INC, 120 MONUMENT CIRCLE, INDIANAPOLIS IN 46260
Gail Boudreaux	director, officer: President and CEO	GENZYME CORP., 500 KENDALL STREET, CAMBRIDGE MA 02142
Dixon Robert L Jr	director	120 MONUMENT CIRCLE, INDIANAPOLIS IN 46204
Felicia F Norwood	officer: Exec VP & President, GBD	120 MONUMENT CIRCLE, INDIANAPOLIS IN 46204
Ronald W Penczek	officer: SVP, Chief Accounting Officer	120 MONUMENT CIRCLE, INDIANAPOLIS IN 46204
Blair Williams Todt	officer: EVP and Chief Legal Officer	8735 HENDERSON ROAD, TAMPA FL 33625
Mark Kaye	officer: EVP & CFO Designate	7 WORLD TRADE CENTER, 250 GREENWICH ST, NEW YORK NY 10007
Gloria M Mccarthy	officer: EVP, Office of the CEO	WELLPOINT, INC, 120 MONUMENT CIRCLE, INDIANAPOLIS IN 46204
Deanna D Strable-soethout	director	C/O PRINCIPAL FINANCIAL GROUP, 711 HIGH ST., DES MOINES IA 50392
Peter D Haytaian	officer: EVP & Pres., Govt. Bus. Div.	220 VIRGINIA AVE, INDIANAPOLIS IN 46204
Susan D. Devore	director	C/O PREMIER, INC., 13034 BALLANTYNE CORPORATE PLACE, CHARLOTTE NC 28277
Ryan M. Schneider	director	1680 CAPITAL ONE DRIVE, MCLEAN VA 22102
John E Gallina	officer: SVP & Chief Accounting Officer	120 MONUMENT CIRCLE, INDIANAPOLIS IN 46204
Julie A Hill	director	WELLPOINT, INC, 120 MONUMENT CIRCLE, INDIANAPOLIS IN 46204